A new drug for the treatment of advanced lung cancer has been approved in the United States

The American regulator has approved the development of Johnson & Johnson’s company for the treatment of one type of lung cancer along with other chemotherapy drugs.

The FDA has approved combination therapy with the drug Rybrevant for patients with non-small cell lung cancer and a mutation in the EGFR protein that causes rapid tumor growth, Reuters reports.

Studies have shown that this drug in combination with chemotherapy reduces the risk of disease progression or death 61% compared to treatment with “chemistry” alone.

In 2021, the FDA approved treatment with this medication under an accelerated schedule. Currently, the effectiveness of Rybrevant has been confirmed by studies of the third stage.

The FDA also approved the drug for the treatment of locally advanced or metastatic non-small cell carcinoma in patients whose disease has progressed on background or after chemotherapy.

“We are redefining the treatment of patients with non-small cell lung cancer, promoting innovative regimens that can be used in the early stages to extend people’s lives”– said Kiran Patel, a specialist at the pharmaceutical company Johnson&Johnson.

Non-small cell lung cancer is the most common type of epithelial lung cancer, which has a high mortality rate.

The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

Although this cancer is associated with smoking, adenocarcinomas can also occur in patients who have never smoked.

We will remind, earlier inScientists have discovered why lung cancer can be resistant to common treatment methods.